drugset / Trial / NCT02665117

Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

NCT02665117

RandomizedParallel-groupDouble-blindPrevention

Summary

Chlorthalidone (CTD) may produce various metabolic disturbances, including hypokalemia, activation of Renin-Angiotensin- Aldosterone (RAA) system, oxidative stress, dyslipidemia, Fibroblast growth factor 23 (FGF23) synthesis, and magnesium depletion. These factors may interact with each other to contribute to the development of insulin resistances and metabolic syndrome. Smaller studies have suggested that Potassium magnesium Citrate (KMgCit) can ameliorate CTD- induced metabolic side effects independent of correction of hypokalemia. This study will tests if KMgCit ameliorates CTD induced metabolic effects independent of correction of hypokalemia.

Timeline

Start
2015-01
Primary completion
2022-11-04
Completion
2022-11-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator POTASSIUM MAGNESIUM CITRATE (4:1:2) Small molecule
Comparator Potassium Chloride Small molecule
Comparator Chlorthalidone Other / unclassified

Indications